Questions people ask about Abnehmspritze Senioren

The question about weight loss injections (GLP-1 agonists like semaglutide) for seniors is complex. Available studies show that these medications can lead to significant weight reduction and improvement in cardiovascular risk factors in older adults (≥65 years). However, long-term data specifically for this age group are lacking. A critical concern is the potential loss of muscle mass (sarcopenia), which is already a problem in seniors. Additionally, gastrointestinal side effects such as nausea and diarrhea can cause dehydration and electrolyte imbalances in older individuals. Costs are often not covered by insurance, and long-term safety is not well established. Therefore, an individual risk-benefit assessment by a specialist is essential, considering comorbidities and concurrent medications. The evidence is mixed: positive short-term results exist, but no robust long-term data for seniors. Caution is warranted.